Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Glucagon on Hepatic Mitochondrial Oxidation in Healthy Humans
NCT03965130Phase 1Completed
- Sponsor
- Yale University
- Start
- Jun 2019
- Primary completion
- Jul 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of glucagon in non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Yale University. Primary endpoint: Rates of Hepatic Mitochondrial Oxidation at 5 hours. Started Jun 2019; status: completed.
02
Drugs
glucagon
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03965130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965130.